MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
BDX stock logo

BDX

Becton, Dickinson and Company

$152.04
2.05
 (1.37%)
Exchange:  NYSE
Market Cap:  55.083B
Shares Outstanding:  325.926M
Delayed data
Calculate BDX Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Instruments & Supplies
   
CEO:  Thomas E. Polen Jr.
Full Time Employees:  70000
Address: 
1 Becton Drive
Franklin Lakes
NJ
07417-1880
US
Website:  https://www.bd.com
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/02/09 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue19,372,00020,178,00021,839,000
Gross Profit8,170,0009,125,0009,924,000
EBITDA4,402,0004,819,0004,957,000
Operating Income2,111,0002,397,0002,578,000
Net Income1,484,0001,705,0001,678,000

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets52,780,00057,286,00055,325,000
Total Liabilities26,983,00031,397,00029,936,000
Total Stockholders Equity25,797,00025,889,00025,390,000
Total Debt15,879,00020,919,00019,181,000
Cash and Cash Equivalents1,416,0001,717,000851,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow2,989,0003,844,0003,430,000
Capital Expenditure-874,000-725,000-760,000
Free Cash Flow2,115,0003,119,0002,670,000
Net Income1,530,0001,705,0001,678,000
Net Change in Cash322,000375,000-1,005,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)21,731,059.839Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)22,163,942.539Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)21,875,000Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)5,025,376.957Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)5,125,482.463Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)5,058,663.579Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)4,699,768.521Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)4,821,716.149Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)4,740,318.196Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)5,311,748.663Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)5,417,558.693Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)5,346,932.127Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)16.510Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)16.790Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)16.370Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)4Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
20.178B  ?P/S
 (TTM)
: 
2.56
?Net Income
 (TTM)
: 
1.705B  ?P/E
 (TTM)
: 
37.28
?Enterprise Value
 (TTM)
: 
71.231B  ?EV/FCF
 (TTM)
: 
22.67
?Dividend Yield
 (TTM)
: 
0.02  ?Payout Ratio
 (TTM)
: 
1.04
?ROE
 (TTM)
: 
0.05  ?ROIC
 (TTM)
: 
0.04
?Net Debt
 (TTM)
: 
17.928B  ?Debt/Equity
 (TTM)
: 
0.72
?P/B
 (TTM)
: 
1.76  ?Current Ratio
 (TTM)
: 
0.94

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
10.22Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates BDX intrinsic value between $157.71 – $221.24 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about BDX valuation

Is Becton, Dickinson and Company (BDX) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Becton, Dickinson and Company (BDX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is BDX a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether BDX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is BDX’s P/E ratio?

You can see BDX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for BDX?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is BDX a good long-term investment?

Whether BDX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

BDX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

1.37
MARKETSnap

Trading Metrics:

Open: 149.72   Previous Close: 149.99
Day Low: 148.7   Day High: 152.55
Year Low: 127.59   Year High: 187.35
Price Avg 50: 150.46   Price Avg 200: 154.33
Volume: 2.215M   Average Volume: 2.869M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
12-05-2026 17:20
Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
BD Appoints Vitor Roque Chief Financial Officer
07-05-2026 06:31
BD Appoints Vitor Roque Chief Financial Officer
BD Reports Second Quarter Fiscal 2026 Financial Results
07-05-2026 06:30
BD Reports Second Quarter Fiscal 2026 Financial Results
Seeking Clues to Becton Dickinson (BDX) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
05-05-2026 10:16
Seeking Clues to Becton Dickinson (BDX) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
BD to Present at Bank of America Securities Health Care Conference
27-04-2026 16:15
BD to Present at Bank of America Securities Health Care Conference
The Healthcare Stock Built for Investors Who Prioritize Capital Preservation
17-04-2026 16:35
The Healthcare Stock Built for Investors Who Prioritize Capital Preservation

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read